Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Ad5-nCoV Vaccine in Healthy Adults
NCT04552366Phase 1Completed
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ad5-ncov in coronavirus disease 2019 (COVID-19) (6 arms). Primary endpoints: Incidence of Adverse Events, Seroconversion rate of IgG antibody against SARS-CoV-2 and 3 more. Started Sep 2020; status: completed.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04552366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552366.